{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:26:38Z","timestamp":1787109998700,"version":"build-2736575974"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2024-04541"],"award-info":[{"award-number":["RGPIN-2024-04541"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105479","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:24:54Z","timestamp":1783639494000},"page":"105479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advancing precision chemotherapy and overcoming resistance mechanisms through sortilin-directed peptide-drug conjugates"],"prefix":"10.1016","volume":"225","author":[{"given":"Bogdan Alexandru","family":"Danalache","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieme Thioro","family":"Faye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5082-7183","authenticated-orcid":false,"given":"Borhane","family":"Annabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.critrevonc.2026.105479_bib1","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2022","journal-title":"Genes. Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib2","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1158\/1538-7445.AM2020-6362","article-title":"Abstract 6362: TH1901, a novel curcumin-peptide conjugate for the treatment of Sortilin-positive (SORT1+) cancer","volume":"80","author":"Annabi","year":"2020","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105479_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/psc.70040","article-title":"Peptide-drug conjugates: A new hope for cancer","volume":"31","author":"Armstrong","year":"2025","journal-title":"J. Pept. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.14740\/wjon1419","article-title":"Tumor dormancy: Biologic and therapeutic implications","volume":"13","author":"Balayan","year":"2022","journal-title":"World J. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105479_bib5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.addr.2007.06.008","article-title":"Endocytic mechanisms for targeted drug delivery","volume":"59","author":"Bareford","year":"2007","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105479_bib6","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3390\/biomedicines9091275","article-title":"Targeting cancer cells overexpressing folate receptors with new terpolymer-based nanocapsules: Toward a novel targeted DNA delivery system for cancer therapy","volume":"9","author":"Bellotti","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12885-021-07854-0","article-title":"Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer","volume":"21","author":"Berger","year":"2021","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105479_bib8","doi-asserted-by":"crossref","first-page":"12865","DOI":"10.1021\/acs.jmedchem.1c00943","article-title":"Reduction of progranulin-induced breast cancer stem cell propagation by sortilin-targeting cyclotriazadisulfonamide (CADA) compounds","volume":"64","author":"Berger","year":"2021","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105479_bib9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/jcmm.15752","article-title":"Overexpression of sortilin is associated with 5-FU resistance and poor prognosis in colorectal cancer","volume":"25","author":"Blondy","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105479_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1331231","article-title":"Elevated sortilin expression discriminates functional from non-functional neuroendocrine tumors and enables therapeutic targeting","volume":"15","author":"Bolduan","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105479_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760787","article-title":"New peptide-drug conjugates for precise targeting of SORT1-mediated vasculogenic mimicry in the tumor microenvironment of TNBC-derived MDA-MB-231 breast and ovarian ES-2 clear cell carcinoma cells","volume":"11","author":"Charfi","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib13","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41419-025-07871-y","article-title":"SORT1 promote the metastasis and invasion of hepatocellular carcinoma via p38\/\u03b2-catenin\/ZEB1 signaling pathway","volume":"16","author":"Chen","year":"2025","journal-title":"Cell. Death Dis."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105479_bib14","first-page":"124","article-title":"Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors","volume":"8","author":"Cheng","year":"2025","journal-title":"Antib. Ther."},{"key":"10.1016\/j.critrevonc.2026.105479_bib15","article-title":"Advances in targeted therapy for tumor with nanocarriers: A review","volume":"31","author":"Cheng","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.critrevonc.2026.105479_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fonc.2013.00193","article-title":"Strategies to increase drug penetration in solid tumors","volume":"3","author":"Choi","year":"2013","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105479_bib17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.2304","article-title":"The cancer stem cell: premises, promises and challenges","volume":"17","author":"Clevers","year":"2011","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105479_bib18","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.3390\/cancers17132102","article-title":"Overcoming barriers in cancer biology research: Current limitations and solutions","volume":"17","author":"Colonna","year":"2025","journal-title":"Cancers"},{"issue":"46","key":"10.1016\/j.critrevonc.2026.105479_bib19","doi-asserted-by":"crossref","first-page":"15407","DOI":"10.1039\/D1SC04656J","article-title":"How to exploit different endocytosis pathways to allow selective delivery of anticancer drugs to cancer cells over healthy cells","volume":"12","author":"Cong","year":"2021","journal-title":"Chem. Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105479_bib20","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3390\/cancers14081877","article-title":"The peptide-drug conjugate TH1902: A new sortilin receptor-mediated cancer therapeutic against ovarian and endometrial cancers","volume":"14","author":"Currie","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105479_bib21","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1158\/1538-7445.AM2024-2071","article-title":"Abstract 2071: Pre-clinical evidence for new camptothecin-peptide conjugates in the treatment of sortilin-positive colorectal cancers","volume":"84","author":"Das","year":"2024","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105479_bib22","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3390\/ph18081198","article-title":"Exploring experimental and in silico approaches for antibody-drug conjugates in oncology therapies","volume":"18","author":"de Almeida","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105479_bib23","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1111\/cas.15086","article-title":"TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer","volume":"112","author":"Demeule","year":"2021","journal-title":"Cancer Sci."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105479_bib24","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.3390\/pharmaceutics14091910","article-title":"The TH1902 docetaxel peptide-drug conjugate inhibits xenografts growth of human SORT1-positive ovarian and triple-negative breast cancer stem-like cells","volume":"14","author":"Demeule","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105479_bib25","article-title":"Sudocetaxel Zendusortide (TH1902) triggers the cGAS\/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing","volume":"15","author":"Demeule","year":"2024","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105479_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cpt.2025.07.001","article-title":"Chemoresistance: The hidden barrier in cancer treatment","volume":"4","author":"Dhiman","year":"2025","journal-title":"Cancer Pathog. Ther."},{"key":"10.1016\/j.critrevonc.2026.105479_bib27","article-title":"A genome-wide CRISPR screen identifies sortilin as the receptor responsible for galectin-1 lysosomal trafficking","author":"Donnelly","year":"2024","journal-title":"bioRxiv"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105479_bib28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/biology14050497","article-title":"Emerging multifunctional biomaterials for addressing drug resistance in cancer","volume":"14","author":"El-Tanani","year":"2025","journal-title":"Biology"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105479_bib29","first-page":"270","article-title":"SORT1 as a novel diagnostic and therapeutic biomarker in chronic lymphocytic leukemia","volume":"11","author":"Farahi","year":"2019","journal-title":"Avicenna J. Med. Biotechnol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105479_bib30","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.apsb.2022.07.020","article-title":"Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?","volume":"13","author":"Fu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105479_bib31","first-page":"169","article-title":"The effect of sortilin silencing on ovarian carcinoma cells","volume":"6","author":"Ghaemimanesh","year":"2014","journal-title":"Avicenna J. Med. Biotechnol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105479_bib32","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.1002\/jcp.30344","article-title":"The multifaceted role of sortilin\/neurotensin receptor 3 in human cancer development","volume":"236","author":"Ghaemimanesh","year":"2021","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41574-022-00737-9","article-title":"Endosomal trafficking in metabolic homeostasis and diseases","volume":"19","author":"Gilleron","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105479_bib34","first-page":"1949","article-title":"Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump","volume":"6","author":"Goren","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/biom16010027","article-title":"From mechanism to medicine: Peptide-based approaches for cancer diagnosis and therapy","volume":"16","author":"Gouveia","year":"2025","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib38","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/ijms24010829","article-title":"Peptide drug conjugates and their role in cancer therapy","volume":"24","author":"Heh","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8096","key":"10.1016\/j.critrevonc.2026.105479_bib39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/d41586-025-04149-3","article-title":"Why cancer can come back years later - and how to stop it","volume":"649","author":"Heidt","year":"2026","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105479_bib40","first-page":"125","article-title":"Ectopic expression of sortilin 1 (NTR-3) in patients with ovarian carcinoma","volume":"1","author":"Hemmati","year":"2009","journal-title":"Avicenna J. Med. Biotechnol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105479_bib41","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/cancers13020242","article-title":"Personalized medicine: Recent progress in cancer therapy","volume":"13","author":"Hoeben","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105479_bib42","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105479_bib43","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1091\/mbc.e03-08-0596","article-title":"Association with membrane protrusions makes ErbB2 an internalization-resistant receptor","volume":"15","author":"Hommelgaard","year":"2004","journal-title":"Mol. Biol. Cell."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105479_bib44","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.neuron.2010.09.034","article-title":"Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin","volume":"68","author":"Hu","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.critrevonc.2026.105479_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117535","article-title":"Mechanistic study of cancer drug delivery: Current techniques, limitations, and future prospects","volume":"290","author":"Imtiaz","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105479_bib46","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3390\/bioengineering12050481","article-title":"Peptide\u2013drug conjugates as next-generation therapeutics: Exploring the potential and clinical progress","volume":"12","author":"Jadhav","year":"2025","journal-title":"Bioengineering"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105479_bib47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/atm-25-34","article-title":"Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment","volume":"13","author":"Jamalinia","year":"2025","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105479_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218174","article-title":"Peptide-drug conjugates in tumor therapy: Current advances and future perspectives","volume":"638","author":"Jin","year":"2026","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib49","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12672-024-01195-7","article-title":"Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy","volume":"15","author":"Joshi","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105479_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5245034","article-title":"Combinatorial approach to improve cancer immunotherapy: rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the immune system","volume":"2019","author":"Joshi","year":"2019","journal-title":"J. Oncol."},{"issue":"6478","key":"10.1016\/j.critrevonc.2026.105479_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105479_bib52","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3390\/life12060897","article-title":"Multidrug resistance of cancer cells and the vital role of P-glycoprotein","volume":"12","author":"Karthika","year":"2022","journal-title":"Life"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib53","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","article-title":"Unveiling the mechanisms and challenges of cancer drug resistance","volume":"22","author":"Khan","year":"2024","journal-title":"Cell. Commun. Signal."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib54","article-title":"Advances in receptor-mediated, tumor-targeted drug delivery","volume":"2","author":"Large","year":"2019","journal-title":"Adv. Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105479_bib55","doi-asserted-by":"crossref","first-page":"9205","DOI":"10.3390\/curroncol30100665","article-title":"Toxicities and quality of life during cancer treatment in advanced solid tumors","volume":"30","author":"Lee","year":"2023","journal-title":"Curr. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105479_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.265","article-title":"Understanding and targeting resistance mechanisms in cancer","volume":"4","author":"Lei","year":"2023","journal-title":"MedComm"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105479_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160042","article-title":"Reducing both Pgp overexpression and drug efflux with anti-cancer gold-paclitaxel nanoconjugates","volume":"11","author":"Li","year":"2016","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s43556-025-00352-w","article-title":"Drug resistance in cancer: molecular mechanisms and emerging treatment strategies","volume":"6","author":"Li","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.critrevonc.2026.105479_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117106","article-title":"Precision targeting in oncology: The future of conjugated drugs","volume":"177","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105479_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117869","article-title":"Design and synthesis of TH19P01-Camptothecin based hybrid peptides inducing effective anticancer responses on sortilin positive cancer cells","volume":"111","author":"Li","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105479_bib61","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.2147\/DDDT.S344052","article-title":"Dynamics of endocytosis and degradation of antibody-drug conjugate T-DM1 in HER2 positive cancer cells","volume":"15","author":"Liang","year":"2021","journal-title":"Drug. Des. Devel Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-025-02328-2","article-title":"Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis","volume":"11","author":"Liang","year":"2026","journal-title":"Sig Transduct. Target. Ther."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105479_bib63","doi-asserted-by":"crossref","first-page":"6042","DOI":"10.3390\/molecules26196042","article-title":"Progress and future directions with peptide-drug conjugates for targeted cancer therapy","volume":"26","author":"Lindberg","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib64","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: Tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105479_bib65","article-title":"Abstract PO5-27-05: Computational design and validation of a novel peptide-drug conjugate for treatment of triple negative breast cancer","volume":"84","author":"Liu","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105479_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216899","article-title":"Unveiling cancer dormancy: Intrinsic mechanisms and extrinsic forces","volume":"591","author":"Liu","year":"2024","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105479_bib67","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","article-title":"Hallmarks of cancer stemness","volume":"31","author":"Loh","year":"2024","journal-title":"Cell. Stem Cell."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105479_bib68","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1021\/acs.jmedchem.5c00007","article-title":"Recent advances in augmenting the therapeutic efficacy of peptide-drug conjugates","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"issue":"33","key":"10.1016\/j.critrevonc.2026.105479_bib69","doi-asserted-by":"crossref","first-page":"15465","DOI":"10.1039\/D4NR02093F","article-title":"Intracellular delivery strategies using membrane-interacting peptides and proteins","volume":"16","author":"Mai","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.critrevonc.2026.105479_bib70","unstructured":"Marsolais, C., Demeule, M., 2023. Targeting SORT1 to unlock the potential of peptide-drug conjugates in oncology. Drug Discovery online. https:\/\/www.drugdiscoveryonline.com\/doc\/targeting-sort1-to-unlock-the-potential-of-peptide-drug-conjugates-in-oncology-0001."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105479_bib71","doi-asserted-by":"crossref","first-page":"11888","DOI":"10.3390\/ijms231911888","article-title":"Deciphering mechanisms of action of sortilin\/neurotensin receptor-3 in the proliferation regulation of colorectal and other cancers","volume":"23","author":"Mazella","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105479_bib72","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2023.41.16_suppl.3089","article-title":"Sudocetaxel Zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study","volume":"41","author":"Meric-Bernstam","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105479_bib73","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"Minchinton","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib74","doi-asserted-by":"crossref","first-page":"54","DOI":"10.35772\/ghm.2022.01062","article-title":"Distress and impacts on daily life from appearance changes due to cancer treatment: A survey of 1,034 patients in Japan","volume":"5","author":"Nozawa","year":"2023","journal-title":"Glob. Health Med."},{"key":"10.1016\/j.critrevonc.2026.105479_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115151","article-title":"Targeted drug conjugate systems for ovarian cancer chemotherapy","volume":"165","author":"Ogundipe","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib76","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell. Metab."},{"key":"10.1016\/j.critrevonc.2026.105479_bib77","article-title":"Targeted endocytosis: Strategies in drug delivery systems for enhancing antitumor efficacy","volume":"258","author":"Peng","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.critrevonc.2026.105479_bib78","series-title":"Design and use of sortilin specific molecular imaging ligands","author":"Peterson","year":"2011"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105479_bib79","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3390\/cancers14030547","article-title":"Metabolic features of tumor dormancy: Possible therapeutic strategies","volume":"14","author":"Pranzini","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105479_bib80","series-title":"Peptide\u2011siRNA program","article-title":"SORT1 delivery system with peptide\u2013oligonucleotide conjugation capability","author":"ProteinQure - Pipeline","year":"2026"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105479_bib81","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/1538-7445.AM2023-3942","article-title":"Abstract 3942: Differential expression of a novel transport receptor, SORT1 (sortilin), in cancer versus healthy tissues that can be utilized for targeted delivery of anti-cancer drugs","volume":"83","author":"Roy","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib82","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12943-025-02357-z","article-title":"Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery","volume":"24","author":"Sabit","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105479_bib83","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/receptors3040021","article-title":"Receptor-based strategies for overcoming resistance in cancer therapy","volume":"3","author":"Sah","year":"2024","journal-title":"Receptors"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105479_bib84","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrc3793","article-title":"Mechanisms of disseminated cancer cell dormancy: an awakening field","volume":"14","author":"Sosa","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105479_bib85","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jconrel.2025.01.060","article-title":"Receptor-ligand interactions for optimized endocytosis in targeted therapies","volume":"380","author":"Sung","year":"2025","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105479_bib86","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2010.04.009","article-title":"The role of HER2 in cancer therapy and targeted drug delivery","volume":"146","author":"Tai","year":"2010","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105479_bib87","first-page":"878","article-title":"Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy","volume":"8","author":"Tannock","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib88","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10555-023-10081-7","article-title":"The role of cancer cell bioenergetics in dormancy and drug resistance","volume":"42","author":"Tau","year":"2023","journal-title":"Cancer Metastas. Rev."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105479_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109979","article-title":"Hallmarks of cancer resistance","volume":"27","author":"Tufail","year":"2024","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib90","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105479_bib91","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","article-title":"Peptides as multifunctional players in cancer therapy","volume":"55","author":"Vadevoo","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"7524","key":"10.1016\/j.critrevonc.2026.105479_bib92","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nature13611","article-title":"Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function","volume":"514","author":"Viale","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib93","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12951-025-03277-2","article-title":"Current progress and remaining challenges of peptide-drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?","volume":"23","author":"Wang","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib94","doi-asserted-by":"crossref","DOI":"10.1080\/19420889.2015.1130192","article-title":"A new role under sortilin's belt in cancer","volume":"9","author":"Wilson","year":"2016","journal-title":"Commun. Integr. Biol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105479_bib95","article-title":"SORT1 targeted peptide-drug conjugates: A new mechanism to extend clinical benefit","volume":"5","author":"Winer","year":"2023","journal-title":"Pharm. Pract. Focus. Oncol."},{"issue":"16_suppl.","key":"10.1016\/j.critrevonc.2026.105479_bib96","article-title":"Long-term efficacy, safety and PK data of TH1902 (Sudocetaxel Zendusortide) in solid tumors: A novel SORT1-targeting peptide-drug-conjugate (PDC)","volume":"42","author":"Winer","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib97","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib98","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105479_bib99","doi-asserted-by":"crossref","first-page":"12217","DOI":"10.2147\/IJN.S548088","article-title":"Current advances in nanocarriers for cancer therapy","volume":"20","author":"Zeinali","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105479_bib100","doi-asserted-by":"crossref","first-page":"11469","DOI":"10.1021\/acs.jmedchem.4c00106","article-title":"Recent advances in targeted cancer therapy: Are PDCs the next generation of ADCs?","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105479_bib101","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:44:13Z","timestamp":1787107453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":101,"alternative-id":["S1040842826003665"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105479","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing precision chemotherapy and overcoming resistance mechanisms through sortilin-directed peptide-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105479"}}